Jubilant Pharmova gets 6 observations from USFDA for its Solid Dosage Manufacturing Facility at Roorkee, India

Jubilant Pharmova Limited today announced that the United States Food and Drug Administration (USFDA) has recently concluded audit of the Solid Dosage Formulations facility at Roorkee, India of Jubilant Generics, a subsidiary of its wholly owned subsidiary Jubilant Pharma Limited.

The US FDA has issued six observations pursuant to the completion of the audit. The company will submit an action plan on the observations and will engage with US FDA for next steps.

Shares of Jubilant Pharmova Limited was last trading in BSE at Rs. 361.05 as compared to the previous close of Rs. 371.50. The total number of shares traded during the day was 29634 in over 2776 trades.

The stock hit an intraday high of Rs. 387.40 and intraday low of 354.00. The net turnover during the day was Rs. 10853509.00.

Source : Equity Bulls

Keywords

JubilantPharmova INE700A01033 SolidDosageFormulations RoorkeeFacility 6Observations USFDAAudit